cabazitaxel Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, taxane derivatives 4153 183133-96-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cabazitaxel
  • jevtana
  • RPR-116258A
  • XRP-6258
  • cabazitaxel acetonate
  • cabazitaxel acetone
  • javtana
a microtubule inhibitor, cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions
  • Molecular weight: 835.94
  • Formula: C45H57NO14
  • CLOGP: 5.44
  • LIPINSKI: 3
  • HAC: 15
  • HDO: 3
  • TPSA: 202.45
  • ALOGS: -5.31
  • ROTB: 15

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 48 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.24 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 74.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 17, 2010 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01CD04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Taxanes
CHEBI has role CHEBI:35610 antineoplastic agent
FDA PE N0000175085 Microtubule Inhibition
FDA EPC N0000175592 Microtubule Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Metastatic Prostate Carcinoma indication
Nutritional disorder contraindication 2492009 DOID:374
Asthenia contraindication 13791008
Hyperbilirubinemia contraindication 14783006 DOID:2741
Nausea and vomiting contraindication 16932000
Dehydration contraindication 34095006
Acute nephropathy contraindication 58574008
Acute infectious disease contraindication 63171007
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Radiation Therapy Involving Bone contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.2 acidic
pKa2 12.4 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
60MG/1.5ML (40MG/ML) JEVTANA KIT SANOFI AVENTIS US N201023 June 17, 2010 RX SOLUTION INTRAVENOUS 10583110 Oct. 27, 2030 INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST
60MG/1.5ML (40MG/ML) JEVTANA KIT SANOFI AVENTIS US N201023 June 17, 2010 RX SOLUTION INTRAVENOUS 8927592 Oct. 27, 2030 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
60MG/1.5ML (40MG/ML) JEVTANA KIT SANOFI AVENTIS US N201023 June 17, 2010 RX SOLUTION INTRAVENOUS May 17, 2020 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
60MG/1.5ML (40MG/ML) JEVTANA KIT SANOFI AVENTIS US N201023 June 17, 2010 RX SOLUTION INTRAVENOUS Sept. 14, 2020 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
60MG/1.5ML (40MG/ML) JEVTANA KIT SANOFI AVENTIS US N201023 June 17, 2010 RX SOLUTION INTRAVENOUS Nov. 17, 2020 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tubulin beta Tumour-associated antigen INHIBITOR SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
4030043 VUID
N0000181529 NUI
C2830183 UMLSCUI
D09755 KEGG_DRUG
51F690397J UNII
8967 INN_ID
447182009 SNOMEDCT_US
996051 RXNORM
27256 MMSL
d07658 MMSL
4030043 VANDF
446706007 SNOMEDCT_US
013461 NDDF
1426815-65-7 SECONDARY_CAS_RN
DB06772 DRUGBANK_ID
CHEBI:63584 CHEBI
6798 IUPHAR_LIGAND_ID
CHEMBL1201748 ChEMBL_ID
9854073 PUBCHEM_CID
C552428 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Jevtana HUMAN PRESCRIPTION DRUG LABEL 1 0024-5824 KIT 60 mg None NDA 21 sections